Skip to main content
CRVO
NASDAQ Life Sciences

Neflamapimod Shows Exposure-Dependent NfL Reduction at 24 Weeks in nfvPPA

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.65
Mkt Cap
$25.265M
52W Low
$1.27
52W High
$10
52W Position info
30% above low
Off High info
84% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CRVO sits 30% above its 52-week low of $1.27.

Summary

CervoMed's 24-week Phase 2a data in nfvPPA show plasma NfL stayed flat overall in the 19 U.S. patients on 40 mg three times daily, and fell a median 4.5 pg/mL in the six patients whose trough drug levels reached at least 4.5 ng/ml. The other 12 patients, with trough levels at or below 3.5 ng/ml, saw NfL rise a median 4.35 pg/mL — roughly in line with the natural-history rate of about 9 pg/mL per year. That split is the point: the drug only looks active above a plasma threshold near 4 ng/ml, consistent with prior DLB and Alzheimer's work, and it supports the new 50 mg tablet designed to push nearly all patients above that level. This follows the 12-week biomarker readout in October and the September 8-K on the FDA lifting the exposure limit. The company still has substantial doubt about continuing as a going concern with $19.6 million in cash, so a DLB partnership remains the funding question. Full 24-week biomarker and clinical data, including the UK 80 mg twice-daily cohort, are due in the first quarter of 2027, with presentation at AD/PD in March 2027.

At the time of this announcement, CRVO was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.3M. The 52-week trading range was $1.27 to $10.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CRVO - Latest Insights

CRVO
Nov 06, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.42
Real-time Price: $1.66 info
Change: +$0.240 (+17%) info
Market Cap: $25.265M info
CRVO
Oct 29, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.66 info
Change: -$0.090 (-5%) info
Market Cap: $25.265M info
CRVO
Oct 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $1.66 info
Change: -$1.36 (-45%) info
Market Cap: $25.265M info
CRVO
Sep 28, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.63
Real-time Price: $1.66 info
Change: -$0.970 (-37%) info
Market Cap: $25.265M info
CRVO
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.64
Real-time Price: $1.66 info
Change: -$0.975 (-37%) info
Market Cap: $25.265M info